

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-32. (Cancelled)

33. (Currently Amended) A pharmaceutical composition comprising a product obtained from a process for obtaining a pharmacologically active composition from a culture of ~~A. camphorate~~ Antrodia camphorata, the process comprising:

- (a) preparing a first culture by inoculating a mycelial inoculum of an isolate of ~~A. camphorate~~ Antrodia camphorata into a liquid medium suitable for growth of said isolate;
- (b) cultivating the first culture resulting from step (a);
- (c) harvesting a pharmacologically active solution by removing a major portion of insoluble substances from the culture of step (b); ~~whereby a pharmacologically active solution is harvested;~~ and
- (d) ~~processing~~ subjecting the solution from step (c) to selective separation based on molecular weight, ~~so as to obtain such that~~ a pharmacologically active composition containing fungal molecules having molecular weights of no more than about 10kDa is obtained.

34. (Currently Amended) A pharmaceutical composition comprising a product obtained from a process for obtaining a pharmacologically active composition from a culture of ~~A. camphorate~~ Antrodia camphorata, the process comprising:

- (a) preparing a first culture by inoculating a mycelial inoculum of an isolate of ~~A. camphorate~~ Antrodia camphorata into a liquid medium suitable for growth of said isolate;
- (b) cultivating the first culture resulting from step (a);

(c) harvesting a pharmacologically active solution by removing a major portion of insoluble substances from the culture of step (b); ~~whereby a pharmacologically active solution is harvested; and~~

(d) ~~processing~~ subjecting the solution from step (c) to selective separation based on molecular weight, so as to obtain such that a pharmacologically active composition containing fungal molecules having molecular weights of no more than about 1kDa is obtained; and

(e) ~~passing~~ subjecting the fraction obtained from step (d) to chromatographic separation based on polarity, through a water-immiscible phase from which the ~~such that a~~ pharmacologically active composition containing fungus-produced hydrophobic compounds of a molecular weight less than or equal to 1 kDa is obtained.

35. (Previously presented) The pharmaceutical composition of claim 34, wherein the process further comprises performing a reverse-phase partition chromatography on the composition from step (e) to obtain pharmacologically active fractions.

36-40. (Cancelled)

41. (New) The pharmaceutical composition of claim 33, wherein the isolate of *Antrodia camphorata* is selected from CCRC 930032, CCRC 35396, CCRC 35398, CCRC 35716, CCRC 36401, and CCRC 36795.

42. (New) The pharmaceutical composition of claim 33, wherein step (b) includes the following sub-steps:

(i) subjecting the first culture obtained in step (a) to a first stage of agitation which is set at a first predetermined rate and for a first period of time to allow growth of the inoculated isolate, such that a second culture with proliferated mycelia is obtained; and

(ii) subjecting the second culture obtained from step (i) to a second stage of agitation which is set at a second predetermined rate higher than the first predetermined rate, so that the isolate grown in the second culture is cultivated under physiological stress.

43. (New) The pharmaceutical composition of claim 42, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.5 to 5.4.

44. (New) The pharmaceutical composition of claim 42, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.6 to 5.3.

45. (New) The pharmaceutical composition of claim 42, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.7 to 5.2.

46. (New) The pharmaceutical composition of claim 33, wherein the liquid medium used in step (a) is potato dextrose broth.

47. (New) The pharmaceutical composition of claim 33, wherein the liquid medium used in step (a) is a synthetic medium containing fructose as a major carbon source.

48. (New) The pharmaceutical composition of claim 34, wherein the chromatographic step (e) is conducted by passing the fraction obtained from step (d) through a stationary water-immiscible phase containing an effective amount of an absorbent capable of selectively adsorbing hydrophobic fungus-produced compounds, and the pharmacologically active composition is obtained by elution of the hydrophobic fungus-produced molecules adsorbed to the stationary phase with an organic solvent.

49. (New) The pharmaceutical composition of claim 48, wherein the stationary water-immiscible phase comprises Amberlite® XAD-4 resin as the absorbent.

50. (New) The pharmaceutical composition of claim 49, wherein the organic solvent has a polarity lower than water.

51. (New) The pharmaceutical composition of claim 50, wherein the organic solvent has a polarity lower than methanol.

52. (New) The pharmaceutical composition of claim 51, wherein the organic solvent is ethyl acetate or ethanol.

53. (New) The pharmaceutical composition of claim 34, wherein the isolate of *Antrodia camphorata* is selected from CCRC 930032, CCRC 35396, CCRC 35398, CCRC 35716, CCRC 36401, and CCRC 36795.

54. (New) The pharmaceutical composition of claim 34, wherein step (b) includes the following sub-steps:

(i) subjecting the first culture obtained in step (a) to a first stage of agitation which is set at a first predetermined rate and for a first period of time to allow growth of the inoculated isolate, such that a second culture with proliferated mycelia is obtained; and

(ii) subjecting the second culture obtained from step (i) to a second stage of agitation which is set at a second predetermined rate higher than the first predetermined rate, so that the isolate grown in the second culture is cultivated under physiological stress.

55. (New) The pharmaceutical composition of claim 54, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.5 to 5.4.

56. (New) The pharmaceutical composition of claim 54, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.6 to 5.3.

57. (New) The pharmaceutical composition of claim 54, wherein sub-steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.7 to 5.2.

58. (New) The pharmaceutical composition of claim 34, wherein the liquid medium used in step (a) is potato dextrose broth.

59. (New) The pharmaceutical composition of claim 34, wherein the liquid medium used in step (a) is a synthetic medium containing fructose as a major carbon source.